AM-2-19

Add links
From Wikipedia, the free encyclopedia

AM-2-19 is an experimental antifungal drug based on amphotericin B (AmB) that is engineered to be less toxic to the kidneys.[1][2][3]

References[edit]

  1. ^ "New antifungal kills without toxic side effects". Science.org. Retrieved 19 November 2023.
  2. ^ Maji, Arun; Soutar, Corinne P.; Zhang, Jiabao; Lewandowska, Agnieszka; Uno, Brice E.; Yan, Su; Shelke, Yogesh; Murhade, Ganesh; Nimerovsky, Evgeny; Borcik, Collin G.; Arango, Andres S.; Lange, Justin D.; Marin-Toledo, Jonnathan P.; Lyu, Yinghuan; Bailey, Keith L.; Roady, Patrick J.; Holler, Jordan T.; Khandelwal, Anuj; SantaMaria, Anna M.; Sanchez, Hiram; Juvvadi, Praveen R.; Johns, Gina; Hageman, Michael J.; Krise, Joanna; Gebremariam, Teclegiorgis; Youssef, Eman G.; Bartizal, Ken; Marr, Kieren A.; Steinbach, William J.; Ibrahim, Ashraf S.; Patterson, Thomas F.; Wiederhold, Nathan P.; Andes, David R.; Pogorelov, Taras V.; Schwieters, Charles D.; Fan, Timothy M.; Rienstra, Chad M.; Burke, Martin D. (8 November 2023). "Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal". Nature. 623 (7989): 1079–1085. Bibcode:2023Natur.623.1079M. doi:10.1038/s41586-023-06710-4. ISSN 1476-4687. PMC 10883201. PMID 37938782. S2CID 265048011.
  3. ^ "Antifungal analog offers reduced toxicity". Chemical & Engineering News. Retrieved 19 November 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=AM-2-19&oldid=1211956733"